featured
Adjuvant Everolimus After Surgery for Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Lancet 2023 Jul 28;[EPub Ahead of Print], CW Ryan, CM Tangen, EI Heath, MN Stein, MV Meng, AS Alva, SK Pal, I Puzanov, JI Clark, TK Choueiri, N Agarwal, RG Uzzo, NB Haas, TW Synold, M Plets, UN Vaishampayan, BM Shuch, IM Thompson, PN LaraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.